The latest update to the Blood Cancer Dashboard, a resource developed in collaboration between Janssen and the Blood Cancer Alliance, has been launched. This includes the expansion of the resource to incorporate incidence and mortality data at a national and local level for Scotland, Wales and Northern Ireland, as well as the latest available waiting times and survival data for England.
The Blood Cancer Dashboard was originally launched in 2019 to bring together for the first time the latest available blood cancer data at both an England and Cancer Alliance level, along with data for the UK’s four most common cancers – breast, colorectal, lung and prostate – across nine key data domains:
- Route to Diagnosis
- Emergency Presentations
- Waiting Times
- Patient Experience
- Time to Diagnosis
Blood cancer is the fifth most common cancer in the UK and the third biggest cancer killer – taking more lives than breast or prostate cancer. There are currently around 250,000 people living with the disease and around 40,000 people diagnosed each year.
By collating the latest available data in an accessible format, the Blood Cancer Dashboard is intended to support clinicians, commissioners, providers and system leaders to identify priority and potential improvement areas in their cancer services. This can be achieved by comparing relevant blood cancer data with national and local level data, and with data for the UK’s four most common cancers.
The data is also intended to support policymakers to track progress against the ambitions set out within the NHS Long Term Plan to see the proportion of cancers diagnosed at stages 1 and 2 increase from half to three-quarters by 2028 and 55,000 more people each year surviving their cancer for at least five years after diagnosis.
“Every patient should have timely access to the right treatment and care. The updated Blood Cancer Dashboard lets the blood cancer community easily analyse local and national data across all four UK nations helping to identify areas of patient need where improvements in cancer services are needed to deliver the best possible outcomes for patients.”
Sarah McDonald, Director of Research, Myeloma UK
Click here to explore the latest available blood cancer data.